[go: up one dir, main page]

WO2007107663A3 - Utilisation du (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phényl}sulfonyl)-2,2-diméthyl-3-thiomorpholine carboxamide ou du (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide dans le traitement de pathologies inflammatoires cutanées - Google Patents

Utilisation du (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phényl}sulfonyl)-2,2-diméthyl-3-thiomorpholine carboxamide ou du (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide dans le traitement de pathologies inflammatoires cutanées Download PDF

Info

Publication number
WO2007107663A3
WO2007107663A3 PCT/FR2007/050939 FR2007050939W WO2007107663A3 WO 2007107663 A3 WO2007107663 A3 WO 2007107663A3 FR 2007050939 W FR2007050939 W FR 2007050939W WO 2007107663 A3 WO2007107663 A3 WO 2007107663A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxy
dimethyl
thiomorpholine
carboxamide
inflammatory skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/050939
Other languages
English (en)
Other versions
WO2007107663A2 (fr
Inventor
Thibaud Biadatti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to EP07731755A priority Critical patent/EP1998779A2/fr
Priority to CA002645327A priority patent/CA2645327A1/fr
Publication of WO2007107663A2 publication Critical patent/WO2007107663A2/fr
Publication of WO2007107663A3 publication Critical patent/WO2007107663A3/fr
Priority to US12/232,456 priority patent/US20090137569A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne l'utilisation d'un composé de formule (I), dans laquelle R correspond à un radical -CH3 ou un radical CH2OH, d'un de ses sels pharmaceutiquement acceptables, solvats pharmaceutiquement acceptables ou hydrates, pour la préparation d'un médicament destiné à prévenir et/ou à traiter les pathologies inflammatoires cutanées. L'invention concerne plus précisément l'utilisation du (3S)-N-hydroxy-4-({4-[(4- hydroxy-2-butynyl)oxy]phényl}sulfonyl)-2,2-diméthyl-3-thiomorpholine carboxamide (ou Apratastat) ou du (S)-N-Hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxamide, d'un de ses sels pharmaceutiquement acceptables, solvats pharmaceutiquement acceptables ou hydrates, pour la préparation d'un médicament destiné à prévenir et/ou à traiter les pathologies inflammatoires cutanées.
PCT/FR2007/050939 2006-03-20 2007-03-16 Utilisation du (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phényl}sulfonyl)-2,2-diméthyl-3-thiomorpholine carboxamide ou du (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide dans le traitement de pathologies inflammatoires cutanées Ceased WO2007107663A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07731755A EP1998779A2 (fr) 2006-03-20 2007-03-16 Utilisation du (3s)-n-hydroxy-4-({4-ý(4-hydroxy-2-butynyl)oxy]phényl}sulfonyl)-2,2-diméthyl-3-thiomorpholine carboxamide ou du (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide dans le traitement de pathologies inflammatoires cutanées
CA002645327A CA2645327A1 (fr) 2006-03-20 2007-03-16 Utilisation du (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide ou du (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxamide dans le traitement de pathologies inflammatoires cutanees
US12/232,456 US20090137569A1 (en) 2006-03-20 2008-09-17 Administration of (3S)-N-hydroxy-4-(sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (S)-N_hydroxy-4-[4_(but-2-ynyloxy)phenylsulfonyl]-2,2-dimethyl thimomorpholine-3-carboxamide for preventing and/or treating inflammatory skin pathologies/afflictions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0602429 2006-03-20
FR0602429A FR2898497B1 (fr) 2006-03-20 2006-03-20 Utilisation de l'apratastat ou du (s)-n-hydroxy-4-(4-but-2- ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carbo xamide dans le traitement de pathologies inflammatoires cutanees

Publications (2)

Publication Number Publication Date
WO2007107663A2 WO2007107663A2 (fr) 2007-09-27
WO2007107663A3 true WO2007107663A3 (fr) 2007-11-22

Family

ID=37057052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/050939 Ceased WO2007107663A2 (fr) 2006-03-20 2007-03-16 Utilisation du (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phényl}sulfonyl)-2,2-diméthyl-3-thiomorpholine carboxamide ou du (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide dans le traitement de pathologies inflammatoires cutanées

Country Status (5)

Country Link
US (1) US20090137569A1 (fr)
EP (1) EP1998779A2 (fr)
CA (1) CA2645327A1 (fr)
FR (1) FR2898497B1 (fr)
WO (1) WO2007107663A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012005229A1 (fr) 2010-07-08 2012-01-12 科研製薬株式会社 Dérivé de n-hydroxyformamide et produit pharmaceutique le contenant
GB2483499A (en) 2010-09-10 2012-03-14 S3 Res & Dev Ltd Diagnostics and Analysis of a Set Top Box
FR3046933B1 (fr) * 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629285A (en) * 1993-08-23 1997-05-13 Immunex Corporation Inhibitors of TNF-α secretion
WO2000044709A2 (fr) * 1999-01-27 2000-08-03 American Cyanamid Company INHIBITEURS D'ENZYME DE CONVERSION DU FACTEUR DE NECROSE TUMORALE α (TACE) CONSISTANT EN DES ACIDES HYDROXAMIQUES DE SULFONAMIDE A BASE D'ACIDE α-AMINE ACETYLENIQUE
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
WO2004032846A2 (fr) * 2002-10-07 2004-04-22 Bristol-Myers Squibb Company Derives de la triazolone et de la triazolethione, inhibiteurs des metalloproteinases de matrices et/ou de l'enzyme de conversion du tnf$g(a)
US20050272929A1 (en) * 2004-06-08 2005-12-08 Wyeth Crystalline polymorphs of (3S)-N-hydroxy-4-({4-[(4-hydroxy-2-butynul)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629285A (en) * 1993-08-23 1997-05-13 Immunex Corporation Inhibitors of TNF-α secretion
WO2000044709A2 (fr) * 1999-01-27 2000-08-03 American Cyanamid Company INHIBITEURS D'ENZYME DE CONVERSION DU FACTEUR DE NECROSE TUMORALE α (TACE) CONSISTANT EN DES ACIDES HYDROXAMIQUES DE SULFONAMIDE A BASE D'ACIDE α-AMINE ACETYLENIQUE
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
WO2004032846A2 (fr) * 2002-10-07 2004-04-22 Bristol-Myers Squibb Company Derives de la triazolone et de la triazolethione, inhibiteurs des metalloproteinases de matrices et/ou de l'enzyme de conversion du tnf$g(a)
US20050272929A1 (en) * 2004-06-08 2005-12-08 Wyeth Crystalline polymorphs of (3S)-N-hydroxy-4-({4-[(4-hydroxy-2-butynul)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LE G T ET AL: "INHIBITORS OF TACE AND CASPASE-1 AS ANTI-INFLAMMATORY DRUGS", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 12, no. 25, 2005, pages 2963 - 2977, XP009063671, ISSN: 0929-8673 *
LEVIN ET AL: "Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 16, no. 6, 15 March 2006 (2006-03-15), pages 1605 - 1609, XP005280762, ISSN: 0960-894X *
YOKOTA K ET AL: "MMP/ADAM inhibitors: Therapeutic potential for psoriasis", EXPERT OPINION ON THERAPEUTIC PATENTS 2005 UNITED KINGDOM, vol. 15, no. 4, 2005, pages 421 - 435, XP002402629, ISSN: 1354-3776 *
ZHANG YUHUA ET AL: "Identification and characterization of 4-((4-(2-butynyloxy) phenyl)sulfonyl)-N-hydroxy-2,2-dimethyl-( 3S)-thiomorpholinecarboxam ide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 309, no. 1, 1 April 2004 (2004-04-01), pages 348 - 355, XP002402583, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
FR2898497A1 (fr) 2007-09-21
WO2007107663A2 (fr) 2007-09-27
CA2645327A1 (fr) 2007-09-27
EP1998779A2 (fr) 2008-12-10
FR2898497B1 (fr) 2008-05-16
US20090137569A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
WO2007103456A3 (fr) Derives de piperazine et piperidine biaryle
NO20080728L (no) Nye 1,4-benzotiazepin-1,1-dioksidderivater som har forbedrede egenskaper, fremgangsmate for fremstilling derav, medikamenter inneholdende nevnte forbindelsene og anvendelse derav
NO20076498L (no) Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren
NZ598582A (en) Novel phenol derivative having uricsuric effect
RU2012103471A (ru) Фармацевтическая композиция, содержащая производное хинолина
TW200745069A (en) Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicaments comprising this compound and its use
NO20074620L (no) Spiroheterocykliske forbindelser og deres anvendelse som medikamenter
WO2007082808A3 (fr) Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
NO20084659L (no) Ko-krystall av C-glucosidderivat og L-prolin
WO2007135527A3 (fr) Composés de benzimidazolyle
TW200833675A (en) Nicotinamide derivatives
NZ561747A (en) (Pyrrol-2-ylmethyl)-indol-1-yl-acetic acid derivatives with PGD2 antagonist activity
WO2007107470A3 (fr) Pyrazoles utiles comme inhibiteurs de 11-beta-hsd-1
WO2009035997A3 (fr) Hétérocycles benzo-fusionnés
WO2009017098A1 (fr) Composition pharmaceutique contenant un composé actif sur le plan optique possédant une activité d'agoniste du récepteur de la thrombopoïétine et son intermédiaire
WO2005074642A3 (fr) Composes chimiques
JP2008189659A5 (fr)
GEP20135730B (en) Trans-4-{2-[4-(2,3-dichlorophe-nyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treatment of schizophrenia
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
NO20064297L (no) Aminoalkoholforbindelse
WO2008008701A3 (fr) Composés thérapeutiques
WO2007096740A3 (fr) Nouvelles céphalosporines
WO2007057221A3 (fr) Composes organiques
WO2007107663A3 (fr) Utilisation du (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phényl}sulfonyl)-2,2-diméthyl-3-thiomorpholine carboxamide ou du (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide dans le traitement de pathologies inflammatoires cutanées

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07731755

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007731755

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2645327

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE